Anthracycline-based adjuvant chemotherapy in breast cancer

The Lancet

Volume 375, Issue 9729, 29 May–4 June 2010, Pages 1870-1871

There are more references available in the full text version of this article.

Current approaches for neoadjuvant chemotherapy in breast cancer
European Journal of Pharmacology, Volume 717, Issues 1–3, 2013, pp. 58-66
Roisin M. Connolly, Vered Stearns
An estimation of the enhanced geothermal systems potential for the Iberian Peninsula
Renewable Energy, Volume 66, 2014, pp. 1-14
César R. Chamorro, …, María M. Linares
SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis
The Lancet Oncology, Volume 17, Issue 7, 2016, pp. 1004-1018
Tarek M A Abdel-Fatah, …, Stephen Y T Chan
Primary endpoints for randomised trials of cancer therapy
The Lancet, Volume 371, Issue 9631, 2008, pp. 2156-2158
Jack Cuzick
In the interest of full disclosure
The Lancet Oncology, Volume 11, Issue 4, 2010, pp. 314-315
Mark E Burkard, …, Kari B Wisinski
Antagonism between tamoxifen and doxorubicin in the MCF-7 human breast tumor cell line
Biochemical Pharmacology, Volume 47, Issue 8, 1994, pp. 1449-1452
Karen E. Woods, …, David A. Gewirtz